Setanaxib not checked
Asahi Kasei Therapeutics, AB · GKT137831 · NOX1/4 inhibitor
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
5 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “1 capsule of 100 mg twice a day for the first 6 weeks of treatment, and 2 capsules of 100 mg twice a day for next 6 weeks of treatment”In the company’s words, NCT02010242 on ClinicalTrials.gov
- Tested for
- Phase 1 (2 trials), Type 2 Diabetes Mellitus With Diabetic Nephropathy, Primary Biliary Cirrhosis, Alport Syndrome
- Main trialPhase 2
- “NADPH oxidase enzymes (NOX) have been implicated in the development of several diabetic complications including diabetic nephropathy. GKT137831 is the first in class NOX1/4 inhibitor. The primary objective of this study is to evaluate the efficacy of oral GKT137831 in patients with residual albuminuria despite maximal inhibition of the renin angiotensin aldosterone system.”In the company’s words, NCT02010242 on ClinicalTrials.gov
- Other names
- GKT137831 · NOX1/4 inhibitor
Other drugs for Phase 1
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- CobimetinibRoche · Phase 2/3
- DivarasibRoche · Phase 3
- EntrectinibRoche · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | Feb 2015 | Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria | |
| Phase 2Completed | 11 Apr 2019 | Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol. | |
| Phase 1/2Completed | 24 Jun 2025 | A Study to Evaluate Setanaxib in Patients With Alport Syndrome | |
| Phase 1Completed | 6 Feb 2019 | Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets | |
| Phase 1Completed | 23 Mar 2021 | Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026